6 terminated. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 6 |
| Phase 2 | 1 | Terminated 1 |
Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine, Capecitabine/eribulin/gemcitabine/vinorelbine - Triple Negative Breast Cancer | Phase 3 | Terminated | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1 | 2022-01-17 | 2024-04-16 |
| A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. Carelizumab, Nab-paclitaxel, Apatinib - Breast Cancer, Triple Negative Breast Cancer | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 80 | 2020-07-14 | 2023-05-06 |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss alpelisib, placebo, nab-paclitaxel - Triple Negative Breast Neoplasms | Phase 3 | Terminated | Novartis Pharmaceuticals | 137 | 2020-06-08 | 2026-09-10 |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) eryaspase (L-asparaginase encapsulated in red blood cells), Gemcitabine, Carboplatin - Triple Negative Breast Cancer | Phase 2 / Phase 3 | Terminated | ERYtech Pharma | 27 | 2019-06-13 | 2022-08-01 |
| A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin - Triple Negative Breast Cancer | Phase 3 | Terminated | Hoffmann-La Roche | 2199 | 2018-08-02 | 2024-08-21 |
| Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer TPC, Bicalutamide 150 mg - Metastatic Triple Negative Breast Cancer | Phase 3 | Terminated | Sun Yat-sen University | 36 | 2016-12-20 | 2021-01-28 |
Breast Neoplasms (1)
Breast Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Breast Neoplasms (5)
130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (1) · Alpelisib (1) · Capecitabine (1) · Carboplatin (1) · Cyclophosphamide (1) · Drug Therapy (1) · Erythrocyte Count (1) · Gemcitabine (1) · Paclitaxel (1) · apatinib (1) · atezolizumab (1) · bicalutamide (1) · camrelizumab (1) · eryaspase (1)
ERYtech Pharma (1) · Hoffmann-La Roche (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Sun Yat-sen University (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)
China (5) · Hungary (3) · Spain (3) · Argentina (2) · Australia (2) · Austria (2) · Belgium (2) · Brazil (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Mexico (2) · Peru (2) · Poland (2)
2016 (1), 2019 (1)